Study timeline and methodological overview. حسب Robert Botelho (20308297)

الموضوعات:

Longitudinal assessment of animal weights and tumor metrics. حسب Robert Botelho (20308297)

الموضوعات:

Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01. حسب Lijuan Liu (136685)

الموضوعات:

Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). حسب Robert Botelho (20308297)

الموضوعات:

Spatial exploration patterns of tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). حسب Robert Botelho (20308297)

الموضوعات:

High-affinity choline Uptake (HACU) in the Cortex, Striatum, and Hippocampus of non-tumor and tumor-bearing mice. حسب Robert Botelho (20308297)

الموضوعات:

MWM training data. حسب Robert Botelho (20308297)

الموضوعات:

Frequency of proestrus in non-tumor and tumor-bearing female mice. حسب Robert Botelho (20308297)

الموضوعات:

Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... حسب Marsel Ganeyev (21453399)

الموضوعات:

Quantification of bacterial adhesion revealed a significant decrease in the adhesion of <i>S. aureus</i>, <i>S. epidermidis</i>, and <i>P. aeruginosa</i> on blotted corneas of mice treated with 0.5% bupivacaine (BUP) combined with topical (TOP) application, following subconjunctival injection (SCI) of CGRP, 24 hours before the final BUP treatment (day 14) and again one hour prior to the final bupivacaine injection on day 15. حسب Ananya Datta (19932144)

List of Included studies. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

The search strategy in three databases. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

NIH score. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

List of excluded studies. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

Comparison of serum VEGF-A165 concentrations pre-bevacizumab administration in patients with increased VEGF-A post-bevacizumab administration and those with decreased VEGF-A. حسب Masashi Okawa (8951294)

الموضوعات:

Microscopic view of <i>spirulina</i> spp. حسب Maha Rehman (17114332)

الموضوعات:

Supplementary data file of graphs. حسب Maha Rehman (17114332)

الموضوعات:

Fig 3 - حسب Maha Rehman (17114332)

الموضوعات:

Fig 5 - حسب Maha Rehman (17114332)

الموضوعات:

Fig 4 - حسب Maha Rehman (17114332)

الموضوعات: